82 related articles for article (PubMed ID: 8297157)
1. Use of a biotinyl-estradiol derivative to demonstrate estradiol-membrane binding sites on adherent human breast cancer MCF-7 cells.
Germain PS; Metezeau P; Tiefenauer LX; Kiefer H; Ratinaud MH; Habrioux G
Anticancer Res; 1993; 13(6A):2347-53. PubMed ID: 8297157
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of fluorescein-conjugated estradiol (E-BSA-FITC) binding in breast cancer suspensions.
Benz C; Wiznitzer I; Lee SH
Cytometry; 1985 May; 6(3):260-7. PubMed ID: 3996141
[TBL] [Abstract][Full Text] [Related]
3. Estradiol membrane binding sites on human breast cancer cell lines. Use of a fluorescent estradiol conjugate to demonstrate plasma membrane binding systems.
Berthois Y; Pourreau-Schneider N; Gandilhon P; Mittre H; Tubiana N; Martin PM
J Steroid Biochem; 1986 Dec; 25(6):963-72. PubMed ID: 3025520
[TBL] [Abstract][Full Text] [Related]
4. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
Kampa M; Nifli AP; Charalampopoulos I; Alexaki VI; Theodoropoulos PA; Stathopoulos EN; Gravanis A; Castanas E
Exp Cell Res; 2005 Jul; 307(1):41-51. PubMed ID: 15922725
[TBL] [Abstract][Full Text] [Related]
5. Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells.
Zhang Y; Kulp SK; Sugimoto Y; Farrar WB; Brueggemeier RW; Lin YC
Anticancer Res; 1998; 18(4A):2541-6. PubMed ID: 9703907
[TBL] [Abstract][Full Text] [Related]
6. Specific binding of estrogen to osteoclast surfaces.
Brubaker KD; Gay CV
Biochem Biophys Res Commun; 1994 Apr; 200(2):899-907. PubMed ID: 8179625
[TBL] [Abstract][Full Text] [Related]
7. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
ter Haar E; Hamel E; Balachandran R; Day BW
Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
[TBL] [Abstract][Full Text] [Related]
8. Internalization and biological effects of serum albumin in the breast cancer MCF-7 and MDA-MB 231 cells.
Germain P; Metezeau P; Hellio R; Habrioux G
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1119-29. PubMed ID: 8747093
[TBL] [Abstract][Full Text] [Related]
9. Sex hormone-binding globulin (SHBG) and estradiol cross-talk in breast cancer cells.
Fortunati N; Catalano MG
Horm Metab Res; 2006 Apr; 38(4):236-40. PubMed ID: 16700004
[TBL] [Abstract][Full Text] [Related]
10. Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
Wiese TE; Polin LA; Palomino E; Brooks SC
J Med Chem; 1997 Oct; 40(22):3659-69. PubMed ID: 9357533
[TBL] [Abstract][Full Text] [Related]
11. Use of confocal microscopy to localize the SHBG interaction with human breast cancer cell lines--a comparison with serum albumin interaction.
Germain P; Egloff M; Kiefer H; Metezeau P; Habrioux G
Cell Mol Biol (Noisy-le-grand); 1997 Jun; 43(4):501-8. PubMed ID: 9220143
[TBL] [Abstract][Full Text] [Related]
12. Enhanced tight junction function in human breast cancer cells by antioxidant, selenium and polyunsaturated lipid.
Martin TA; Das T; Mansel RE; Jiang WG
J Cell Biochem; 2007 May; 101(1):155-66. PubMed ID: 17243118
[TBL] [Abstract][Full Text] [Related]
13. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Prosperi JR; Robertson FM
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):55-70. PubMed ID: 16997132
[TBL] [Abstract][Full Text] [Related]
15. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells.
Koli KM; Arteaga CL
Cancer Res; 1997 Mar; 57(5):970-7. PubMed ID: 9041203
[TBL] [Abstract][Full Text] [Related]
16. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.
Neubauer H; Adam G; Seeger H; Mueck AO; Solomayer E; Wallwiener D; Cahill MA; Fehm T
Climacteric; 2009 Jun; 12(3):230-9. PubMed ID: 19340614
[TBL] [Abstract][Full Text] [Related]
17. DDT mimicks estradiol stimulation of breast cancer cells to enter the cell cycle.
Dees C; Askari M; Foster JS; Ahamed S; Wimalasena J
Mol Carcinog; 1997 Feb; 18(2):107-14. PubMed ID: 9049186
[TBL] [Abstract][Full Text] [Related]
18. Can transforming growth factor-beta1 and retinoids modify the activity of estradiol and antiestrogens in MCF-7 breast cancer cells?
Czeczuga-Semeniuk E; Anchim T; Dziecioł J; Dabrowska M; Wołczyński S
Acta Biochim Pol; 2004; 51(3):733-45. PubMed ID: 15448735
[TBL] [Abstract][Full Text] [Related]
19. Measurement of ligand binding, E-BSA-FITC.
Ashcroft RG
Cytometry; 1986 May; 7(3):298-9. PubMed ID: 3709312
[No Abstract] [Full Text] [Related]
20. Sex hormone binding globulin inhibits strongly the uptake of estradiol by human breast carcinoma cells via a deprivative mechanism.
Zeginiadou T; Kortsaris AH; Koliais S; Antonoglou O
Cancer Biochem Biophys; 1998 Oct; 16(3):253-63. PubMed ID: 10072209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
